Member Info for LlamaFarmer

1.6p ? that's an under promise and over deliver.

I know that reads ridiculous as we are at 0.20p but add a NHS contract, roll it out into Europe ( not just the current Portugal ) and increase the Northern and Southern U.S.A .licensing agreements.

THEN, go and find any other Pharma that fills an unmet need that is only worth £100m - genuine question what's their names?

Interesting, SS

RNS holding 196351963

Prospectus advised his holding would be 167,956,856, he likes Solvonis then.

We've got small cap traders hitting the small stuff, they'll run up and down if they like it.

Looks like at least one large holder selling as well, sometimes things change and people need money, we've had two large holders not TR1 yet and one who has dipped just under the 3% and doesn't need to report.

Pamlico Shoals 12.36% 730m

Steven Myers 5.89% 348m

Stuart Sharpless 2.84% 168m

If any of them decided to liquidate with an average volume of 49m shares a day traded and them not selling as much on down days we should be there or therabouts?

Medical-assisted psychotherapy allows for deeper introspection, and greater breakthroughs when combined with one on one counseling. It has shown to be an incredibly effective therapy.

PTSD is being treated as well ... Just a matter of time.

I've bought what I want to hold, critical mass wont be too far away imo.

"More than 70% of patients with treatment-resistant depression (including bipolar patients) experience rapid relief after a low-dose infusion. Similar success rates have been seen in returning combat veterans suffering from PTSD."

Https://revitalistclinic.com/?srsltid=AfmBOoqcfBVRYF6rWyjHyDXKR04WragCzc7o8mEDP10jf7HuRBAUc-p3

INNOVATIVE KETAMINE THERAPY PROVIDING RAPID RELIEF FOR MENTAL HEALTH & CHRONIC PAIN

Infusion therapy is an innovative, safe and effective approach that has been shown to help with depression, PTSD and many other mood disorders. Learn more about how these new therapies can help you or a loved one.

FREE ASSESSMENT

The U.S. alcohol and substance addiction treatment industry is significant with 14,000+ treatment facilities across the country generating more than $35bn in revenue, even with its low efficacy rates. Awakn aims to improve performance of this industry by providing clinic operators with access to an efficient and effective treatment option under license.

USA current efficacy rates of 25% - Awakn/ SVNS at 86%.

As they say in America - Do The Math!

Dec 2023 Awakn purchase the world wide Licensing rights to its Esketamine formula from LTS

If you look into the LTS purchase the Esketamine formula that SVNS own the world wide rights to is registered in the UK, EU,USA, China & Japan.

Chinese and Japanese cultures and problems with alcohol ... Un tapped Licensing agreements ... Unmet medical needs.

Not much is made of the current Awakn Licensing agreements ...

Dec 2023 Awakn purchase the world wide Licensing rights to its Esketamine formula from LTS

https://www.ltslohmann.com/en/press-releases/lts-and-awakn-life-sciences-enter-into-global-licensing-agreement/

https://thedalesreport.com/psychedelics/awakn-life-sciences/

Then they in turn license it (Esketamine ) in North America, Southern States America, Portugal ...

https://www.newsfilecorp.com/release/133631/Awakn-Life-Sciences-Expands-Commercial-Operations-into-the-U.S.-First-Licensing-Partnership-Agreement-with-Revitalist

Toronto, Ontario--(Newsfile Corp. - August 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) ("Revitalist"), one of the largest publicly listed U.S. based ketamine wellness-clinic chains. The agreement will enable Revitalist to treat clients with Awakn's proprietary ketamine-assisted therapy for the treatment of AUD.

Awakn's proprietary treatment was developed and validated in a Phase II a/b trial. The results of the trial were published in January 2022 in the American Journal of Psychiatry. The trial delivered 86% abstinence over the six-months post treatment versus 2% pre-trial. The current standard of care has an approximate 25% abstinence rate over the same timeframe.

Under the terms of the license agreement, signed May 18, 2023, and launched April, 2024, Awakn provides access to its proprietary therapeutics and training to the Rivus practitioners, and in return, Rivus will pay Awakn an annual fee and a revenue share per treatment.

“We are excited to partner with Rivus and their excellent team, there is shared ethos and vision between the two organizations which is important. Being able to provide a whole new cohort of people in Oklahoma with a new more effective treatment option whilst they are in desperate need, is what drives us.”

– Anthony Tennyson, Awakn CEO

READ ONE LINE AGAIN: "Awakn's proprietary treatment was developed and validated in a Phase II a/b trial."

Hello U.S.A.

Read him the stats from the online data.

"That will do very well, it's a massive, unmet need"

I was talking to a pharmacologist this week and told him about the More - Kare trial.

When I showed him the numbers i.e 50% heavy drinking and 86% abstinence longer term he paused and said, that is really very good, there is nothing out there like this, are you sure of your numbers?

DVH - the large 20m trade last night didn't tie up directly to any holding I could see but did make me wonder if it was a partial and end trade for someone split into two and that was after the 5m's ?

Hence the late 4.7m ;)

Pamlico Shoals 730,306,344 12.36% No TR1

Steven Myers 348,269,230 5.89% - No TR1

Stuart Sharpless - 167,956,856 No TR1 required at 2.84%

Spreadex - 242961538 4.11% have TR1

William Potts 610,461,538 10.33% - Mr Potts has TR1 his holding https://www.lse.co.uk/rns/SVNS/holdings-in-company-g4ch4qvi2hrij41.html

Oberon -189613635 have TR1 3.2%

N.Nelson - 205,961,538 have TR1 3.49%

If they haven't TR1 is it more likely to be one of them or Spreadex taking the quick win?

In all honesty let the market soak them up at these low prices on the soft news rather than into a rising market when the "Hard news" starts arriving?

There's stock available.

All about the crypto gains, as ppl pull away from those plays they'll look for more traditional holds and flips.

Novo Nordisk worth looking at for your research once Ozempic was allowed for fatties, instant rerate for large unmet need.

SVNS only deals with large unmet needs, that's why the Govts of UK and USA are fast tracking them.

No where near 5 - 10 years, 5 - 10 months more likely time scale.

SVN 001 on phase 3 with NHS - they have accelerated the trial by opening to more sites, plus have advised in the trial info being rolled out into the NHS as soon as results are in - read it!

002 - FDA allowed them to use competitors data to speed up trial results, also granting "tickets" to a one day, fast track review board - Dennis Purcell the CEO is a U.S. citizen, a Life Science funding specialist and runs $15B Life Sciences Co Aisling Capital, that improves their chances of getting a ticket.

CNS Library is available to be licensed - that gives immediate value - look at what Awakn have done previously in this area ( Awakn purchased by GPL and renamed as Solvonis).

I imagine it will be in the preclinical and Phase 3 stage of its development you will see further indications.

Once the mid term data on SVN 001 and SVN 002 are in and digested, plus, now the FDA Patent has added value to the whole product range and "library" it will be on peoples radars.

Looking at the composition of the BOD and the retained Co they are going to attempt to develop these with partners to grow the value into different income streams and territories.

The game will be, can the large unmet societal needs that they are addressing be allowed to remain single or does it have to be part of a much larger entity i.e £70 - £280M early doors buyout or into the Billions of £ if sucessful development of 001/002/014 and CNS Library.

Either way is a winner for the BOD and is why they are buying and holding stock, options and warrants.

It is equally good for the P.I. who are holding.

Whoever is buying is doing so very cleverly and very quietly.

They know this is the relative, news dead period of the cycle where the share price is still close to the placing price of 0.13p and the PI market is off chasing bitcoin treasury plays with a market cap of $1.36B and coins valued at cost of $56M.

To explain that, all of the newsflow released so far has been 'soft news'

"We are going to use AI to go through our CNS Library" - Do some reading - the CNS Library has already been computed.

" Patent on CNS "we received a first-action allowance with no objections or rejections" - Means we are being granted a patent over the USA for CNS Library", first step is this, the second step is the issue of the patent, step one leads to step two, it has been granted.

SVN 014 - The Company has now completed the synthesis of development candidates, marking the third of seven stages in the SVN-SDN-014 translational development plan. This latest phase involved the synthesis of a focused set of compounds for subsequent preclinical characterisation, including pharmacological and toxicological profiling.

Further details of the remaining stages can be found in the Company's announcement on 18 March 2025. - if you do look back at this previous RNS you realise" Awakn has now contracted Concept Life Sciences ("Concept"), the acquirer of Charnwood, to complete the remaining synthesis. Following a brief pause for knowledge transfer, work has now resumed, and completion is expected by end-May 2025."

Further reading informs this end May 2025 date has been moved back to End July 2025.

They are running SVN 001 and SVN 002 in parallel studies for a potential double whammy, each trial supporting the other, slightly different doseages being trialled at the same time to ensure a successful candidate is achieved, thin film esketamine 0.5mg (fda), Ketamine drip t 0.80mg or 0.05mg (NHS ) plus double blind placebo - pick a card any card.

They have retained a specialist Non Exec Director to deal with licensing and bringing new drugs to market, she is also being consulted by Novo Nordisk, specifically for their Ozempic drug!

Also retained a specialist Licensing, mergers & Acquisition business.

Everything slowly pushing along and building to a crescendo.

Shhhh

You go and mingle

Each company has a maximum slot of 20 minutes to present followed by a Q&A session for a further 10 minutes. Once all the companies have presented, networking continues for a further 90 minutes over wine and canapés. Our forums are completely free to attend, but we do actively vet our audience to ensure attendees on the night are genuine members of the investment community.